title: Effectiveness and cost effectiveness of human papillomavirus vaccine: a systematic review.
abstract: The recent approval of human papillomavirus (HPV) vaccine means that decision makers need information beyond that available from randomized clinical trials to recommend funding for this vaccination programme. Modelling and economic studies have addressed some of those information needs. We conducted a qualitative systematic review to summarize the existing data. Review articles were obtained from an extensive literature search on studies using mathematical modelling (either a Markov or transmission dynamic model) to determine the effectiveness or cost effectiveness of an HPV vaccine compared with the current cytology-based Pap smear screening programme. A total of 21 studies (but 22 models) were included in the review after being assessed for methodological quality. All of the included studies had used a mathematical model to determine the effectiveness of an HPV vaccine, whilst 13 had also conducted a cost-effectiveness analysis. Although the studies used different model structures, baseline parameters and assumptions, all studies showed that vaccination would decrease rates of HPV infection, precancerous lesions and cervical cancer. Studies had a consistent message with respect to cost effectiveness: a female-only vaccination programme is cost effective compared with the current cytology-based Pap smear screening programme, while the cost effectiveness of a male and female vaccination programme is generally not cost effective compared with female-only vaccination.
authors.affiliation: University of British Columbia, Vancouver, British Columbia, Canada. fawziah.marra@bccdc.ca
authors.forename: Fawziah
authors.initials: F
authors.lastname: Marra
authors.forename: Karine
authors.initials: K
authors.lastname: Cloutier
authors.forename: Bridgette
authors.initials: B
authors.lastname: Oteng
authors.forename: Carlo
authors.initials: C
authors.lastname: Marra
authors.forename: Gina
authors.initials: G
authors.lastname: Ogilvie
mesh_terms: D003362:Cost-Benefit Analysis; D055088:Early Detection of Cancer; D005260:Female; D006801:Humans; D017589:Immunization Programs / Q000191:economics*; D008390:Markov Chains; D018803:Models, Economic; D030361:Papillomavirus Infections / Q000191:economics / Q000517:prevention & control*; D053918:Papillomavirus Vaccines / Q000191:economics* / Q000627:therapeutic use; D002583:Uterine Cervical Neoplasms / Q000191:economics / Q000517:prevention & control* / Q000821:virology; D016387:Women's Health
chemical_list: D053918:Papillomavirus Vaccines